BPG is committed to discovery and dissemination of knowledge
Featured Articles
5/28/2018 1:11:50 AM | Browse: 1179 | Download: 1505
Publication Name World Journal of Nephrology
Manuscript ID 38247
Country Italy
ISSN 2220-6124 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Urology & Nephrology
Manuscript Type Review
Article Title Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy
Manuscript Source Invited Manuscript
All Author List Maurizio Salvadori and Aris Tsalouchos
Funding Agency and Grant Number
Corresponding Author Maurizio Salvadori, MD, Professor, Department of Nephrology and Renal Transplantation, Careggi University Hospital, viale Pieraccini 18, Florence 50139, Italy. maurizio.salvadori1@gmail.com
Key Words Rapidly progressive glomerulonephritis; Remission induction therapy; Antineutrophil cytoplasmic antibody associated vasculitides; Cyclophosphamide; Rituximab; Corticosteroids; Plasma exchange; Avacopan
Core Tip Antineutrophil cytoplasmic antibody (ANCA) associated vasculitides with renal involvement, presents as Rapidly Progressive Glomerulonephritis, are organ-threatening and potentially life-threatening diseases. Although remission induction immunosuppressive regimens overall have been very successful in the treatment of these conditions, many questions remain unanswered. The still open challenges and questions concern: (1) The choice of the first-line therapy (cyclophosphamide versus rituximab) based on renal function at baseline, new versus relapsed disease, ANCA specificity, tissue injury and safety; (2) the role of plasma exchange in combination with steroid and non steroid agents and (3) the advent of novel target therapies and strategies.
Publish Date 2018-05-07 04:12
Citation Salvadori M, Tsalouchos A. Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy. World J Nephrol 2018; 7(3): 71-83
URL http://www.wjgnet.com/2220-6124/full/v7/i3/71.htm
DOI http://dx.doi.org/10.5527/wjn.v7.i3.71
Full Article (PDF) WJN-7-71.pdf
Full Article (Word) WJN-7-71.doc